Physician profile
Howard Shaw
NPI 1255379509
$1,051.26
in general payments reported to CMS, 2019-2025
15 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $114 · 2021: $258 · 2022: $39.17 · 2023: $273 · 2024: $16.14 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $203.73 | 2019-2020 | |
| Shield Therapeutics INC | $197.27 | 2023-2025 | Accrufer |
| Davol INC. | $146.79 | 2021 | |
| Mayne Pharma Commercial LLC | $125.00 | 2023 | |
| Evofem Biosciences, INC. | $82.73 | 2021-2025 | Solosec, Phexx, Phexxi |
| Abbvie INC. | $54.13 | 2022-2023 | Lo Loestrin Fe |
| Avion Pharmaceuticals | $47.06 | 2021-2023 | Balcoltra |
| Myovant Sciences INC. | $37.06 | 2021-2022 | |
| Therapeuticsmd, INC. | $32.63 | 2020 | |
| Vertical Pharmaceuticals, LLC | $23.57 | 2019 | |
| Merck Sharp & Dohme LLC | $22.80 | 2023 | Gardasil 9 |
| Astellas Pharma US INC | $22.00 | 2023 | Veozah |
| Sumitomo Pharma America, INC. | $20.77 | 2023 | Myfembree |
| Agile Therapeutics, INC. | $19.58 | 2023 | Twirla |
| Biogen, INC. | $16.14 | 2024 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.